🧠 Ask this record

Get an AI answer drawn only from the Pfizer Documents (PHMPT/FDA) documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.

2373 documents

125742 45 S321 M1 356h

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 10 pages

05/09/2022 BioNTech Manufacturing GmbH +49 (0) 6131 9084-7593 +49 (0) 6131 9084-390 An der Goldgrube 12 Mainz N/A Germany 55131 [email protected] 117645848 2229 Kathleen Collins, Senior Director, Global Regulatory Affairs 125742 45 [COVID-19 mRNA Vaccine (nucleoside modified)] COMIRNATY [COVID-19 Vaccine (BNT162, PF-07302048)] Liquid 30 mcg Intramuscular Active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 16 years of age COVID-19; SARS-CoV-2; Disease caused by…

125742 45 S316 M1 356h

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 10 pages

05/04/2022 BioNTech Manufacturing GmbH +49 (0) 6131 9084-7593 +49 (0) 6131 9084-390 An der Goldgrube 12 Mainz N/A Germany 55131 [email protected] 117645848 2229 Kathleen Collins, Senior Director, Global Regulatory Affairs 125742 45 [COVID-19 mRNA Vaccine (nucleoside modified)] COMIRNATY [COVID-19 Vaccine (BNT162, PF-07302048)] Liquid 30 mcg Intramuscular Active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 16 years of age COVID-19; SARS-CoV-2; Disease caused by…

125742 45 S314 M1 356h

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 10 pages

05/02/2022 BioNTech Manufacturing GmbH +49 (0) 6131 9084-7593 +49 (0) 6131 9084-390 An der Goldgrube 12 Mainz N/A Germany 55131 [email protected] 117645848 2229 Kathleen Collins, Senior Director, Global Regulatory Affairs 125742 45 [COVID-19 mRNA Vaccine (nucleoside modified)] COMIRNATY [COVID-19 Vaccine (BNT162, PF-07302048)] Liquid 30 mcg Intramuscular Active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 16 years of age COVID-19; SARS-CoV-2; Disease caused by…

125742 45 S312 M1 356h

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 10 pages

04/29/2022 BioNTech Manufacturing GmbH +49 (0) 6131 9084-7593 +49 (0) 6131 9084-390 An der Goldgrube 12 Mainz N/A Germany 55131 [email protected] 117645848 2229 Kathleen Collins, Senior Director, Global Regulatory Affairs 125742 45 [COVID-19 mRNA Vaccine (nucleoside modified)] COMIRNATY [COVID-19 Vaccine (BNT162, PF-07302048)] Liquid 30 mcg Intramuscular Active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 16 years of age COVID-19; SARS-CoV-2; Disease caused by…

125742 45 S279 M1 356h

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 10 pages

03/18/2022 BioNTech Manufacturing GmbH +49 (0) 6131 9084-7593 +49 (0) 6131 9084-390 An der Goldgrube 12 Mainz N/A Germany 55131 [email protected] 117645848 2229 Kathleen Collins, Senior Director, Global Regulatory Affairs 125742 0045 [COVID-19 mRNA Vaccine (nucleoside modified)] COMIRNATY [COVID-19 Vaccine (BNT162, PF-07302048)] Liquid 30 mcg Intramuscular Active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 16 years of age COVID-19; SARS-CoV-2; Disease caused by…

125742 45 S276 M1 356h

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 10 pages

03/16/2022 BioNTech Manufacturing GmbH +49 (0) 6131 9084-7593 +49 (0) 6131 9084-390 An der Goldgrube 12 Mainz N/A Germany 55131 [email protected] 117645848 2229 Kathleen Collins, Senior Director, Global Regulatory Affairs 125742 0045 [COVID-19 mRNA Vaccine (nucleoside modified)] COMIRNATY [COVID-19 Vaccine (BNT162, PF-07302048)] Liquid 30 mcg Intramuscular Active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 16 years of age COVID-19; SARS-CoV-2; Disease caused by…

125742 45 S273 M1 356h

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 10 pages

03/15/2022 BioNTech Manufacturing GmbH +49 (0) 6131 9084-7593 +49 (0) 6131 9084-390 An der Goldgrube 12 Mainz N/A Germany 55131 [email protected] 117645848 2229 Kathleen Collins, Senior Director, Global Regulatory Affairs 125742 0045 [COVID-19 mRNA Vaccine (nucleoside modified)] COMIRNATY [COVID-19 Vaccine (BNT162, PF-07302048)] Liquid 30 mcg Intramuscular Active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 16 years of age COVID-19; SARS-CoV-2; Disease caused by…

125742 45 S271 M1 356h

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 10 pages

03/11/2022 BioNTech Manufacturing GmbH +49 (0) 6131 9084-7593 +49 (0) 6131 9084-390 An der Goldgrube 12 Mainz N/A Germany 55131 [email protected] 117645848 2229 Kathleen Collins, Senior Director, Global Regulatory Affairs 125742 0045 [COVID-19 mRNA Vaccine (nucleoside modified)] COMIRNATY [COVID-19 Vaccine (BNT162, PF-07302048)] Liquid 30 mcg Intramuscular Active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 16 years of age COVID-19; SARS-CoV-2; Disease caused by…

125742 45 S267 M1 356h

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 10 pages

03/01/2022 BioNTech Manufacturing GmbH +49 (0) 6131 9084-7593 +49 (0) 6131 9084-390 An der Goldgrube 12 Mainz N/A Germany 55131 [email protected] 117645848 2229 Kathleen Collins, Senior Director, Global Regulatory Affairs 125742 0045 [COVID-19 mRNA Vaccine (nucleoside modified)] COMIRNATY [COVID-19 Vaccine (BNT162, PF-07302048)] Liquid 30 mcg Intramuscular Active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 16 years of age COVID-19; SARS-CoV-2; Disease caused by…

125742 45 S252 M1 356h

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 10 pages

02/02/2022 BioNTech Manufacturing GmbH +49 (0) 6131 9084-7593 +49 (0) 6131 9084-390 An der Goldgrube 12 Mainz N/A Germany 55131 [email protected] 117645848 2229 Kathleen Collins, Senior Director, Global Regulatory Affairs 125742 0045 [COVID-19 mRNA Vaccine (nucleoside modified)] COMIRNATY [COVID-19 Vaccine (BNT162, PF-07302048)] Liquid 30 mcg Intramuscular Active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 16 years of age COVID-19; SARS-CoV-2; Disease caused by…

125742 45 S244 M1 356h

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 10 pages

01/28/2022 BioNTech Manufacturing GmbH +49 (0) 6131 9084-7593 +49 (0) 6131 9084-390 An der Goldgrube 12 Mainz N/A Germany 55131 [email protected] 117645848 2229 Adrienne Stafford, Director, Pfizer Global CMC - Vaccines 4300 Oak Park Road Sanford NC 27330919-708-6173 [email protected] 125742 0045 [COVID-19 mRNA Vaccine (nucleoside modified)] COMIRNATY COVID-19 Vaccine (BNT162, PF-07302048) Liquid 30 mcg Intramuscular Active immunization to prevent COVID-19 caused by SARS-CoV-2…

125742 45 S211 M1 356h

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 7 pages

12/16/2021 BioNTech Manufacturing GmbH +49 (0) 6131 9084-7593 +49 (0) 6131 9084-390 An der Goldgrube 12 Mainz N/A Germany 55131 [email protected] 117645848 2229 Amit Patel, Director, Pfizer Global Regulatory Affairs - Vaccines 235 East 42nd Street New York NY 10017214-918-5262 845-474-3500 [email protected] 125742 0045 [COVID-19 mRNA Vaccine (nucleoside modified)] COMIRNATY COVID-19 Vaccine (BNT162, PF-07302048) Liquid 30 mcg Intramuscular Active immunization to prevent COVID-19…

125742 45 S314 M1 cover

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 2 pages

Pfizer Global Regulatory Affairs Pfizer Inc. 235 East 42ndStreet/New York , NY 10017 -5755 Global Product Developm ent 02May 2022 Peter Marks , M.D., Ph.D. Active Office Director Office of Vaccines Research and Review Food and Drug Administr ation Center for Bi ologics Evaluation and Research DocumentControl Center 10903 New Hampshire Avenue WO71, G112 Silver Spring, MD 20993 -0002THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION WITH…

125742 45 S312 M1 cover

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 2 pages

Pfizer Global Regulatory Affairs Pfizer Inc. 235 East 42ndStreet/New York , NY 10017 -5755 Global Product Developm ent 29April2022 Peter Marks , M.D., Ph.D. Active Office Director Office of Vaccines Research and Review Food and Drug Administr ation Center for Bi ologics Evaluation and Research DocumentControl Center 10903 New Hampshire Avenue WO71, G112 Silver Spring, MD 20993 -0002THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION WITH…

125742 45 S279 M1 cover

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 2 pages

Pfizer Global Regulatory Affairs Pfizer Inc. 235 East 42ndStreet/New York , NY 10017 -5755 Global Product Developm ent 18March2022 Peter Marks , M.D., Ph.D. Active Office Director Office of Vaccines Research and Review Food and Drug Administr ation Center for Bi ologics Evaluation and Research DocumentControl Center 10903 New Hampshire Avenue WO71, G112 Silver Spring, MD 20993 -0002THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION WITH…

125742 45 S276 M1 cover

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 2 pages

Pfizer Global Regulatory Affairs Pfizer Inc. 235 East 42ndStreet/New York , NY 10017 -5755 Global Product Developm ent 16March2022 Peter Marks , M.D., Ph.D. Active Office Director Office of Vaccines Research and Review Food and Drug Administr ation Center for Bi ologics Evaluation and Research DocumentControl Center 10903 New Hampshire Avenue WO71, G112 Silver Spring, MD 20993 -0002THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION WITH…

125742 45 S273 M1 cover

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 2 pages

Pfizer Global Regulatory Affairs Pfizer Inc . 235 East 42ndStreet /New York , NY 10017 -5755 Global Product Developm ent 15March 2022 Peter Marks , M.D., Ph.D. Active Office Director Office of Vaccines Research and Review Food and Drug Administr ation Center for Bi ologics Evaluation and Research Document Control Center 10903 New Hampshire Avenue WO71, G112 Silver Spring, MD 20993 -0002THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION …

125742 45 S271 M1 cover

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 2 pages

Pfizer Global Regulatory Affairs Pfizer Inc. 235 East 42ndStreet/New York , NY 10017 -5755 Global Product Developm ent 11March2022 Peter Marks , M.D., Ph.D. Active Office Director Office of Vaccines Research and Review Food and Drug Administr ation Center for Bi ologics Evaluation and Research DocumentControl Center 10903 New Hampshire Avenue WO71, G112 Silver Spring, MD 20993 -0002THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION WITH…

125742 45 S267 M1 cover

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 12 15 Documents · 2 pages

Pfizer Global Regulatory Affairs Pfizer Inc. 235 East 42ndStreet/New York , NY 10017 -5755 Global Product Developm ent 01March2022 Peter Marks , M.D., Ph.D. Active Office Director Office of Vaccines Research and Review Food and Drug Administr ation Center for Bi ologics Evaluation and Research DocumentControl Center 10903 New Hampshire Avenue WO71, G112 Silver Spring, MD 20993 -0002THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION WITH…

125742 S1 M5 CRF c4591001 1260 12601108

Pfizer Documents (PHMPT/FDA) · Pfizer Bla Submission / Pfizer 16 Plus Documents · 227 pages

Page 1 of 227 ***Confidential*** Header Text: c4591001 Visit: COHORT_SELECTION Form: COHORT SELECTION Form Version: 30-Jul-2020 21:29 Form Status: Data Complete, Locked, Frozen, Verified Site No: 1260 Site Name: (1260) UMass Memorial Medical Center Subject No: 12601108 Subject Initials: --- Generated By: Generated Time (GMT): 29-Mar-2021 18:51 eCRF Audit Trail History Cohort Selection DO NOT USE THE OPTIONS STAGE 1 NONSENTINEL and STAGE 2 from this CRF. As per protocol amendment 5, STAGE 3…